Myopia

Alonso discusses his recent study highlighting pupil constriction in accommodative eye vergence as the central mechanism driving myopia progression.

This evidence-based eye care podcast seeks to turn research into practical clinical decisions, with new episodes on the first Monday of each month featuring expert guests across glaucoma, retina, dry eye, AI, and more.

The study evaluated the company’s Defocus Incorporated Multiple Segments Triple Enhanced Design (DIMS TED) myopia control lenses in children aged 4–12 with progressive myopia.

The lens was developed in collaboration with Brien Holden Vision Institute (BHVI).

Evolutions in AI, myopia management, and individualized care are on ODs' minds for the new year.

Understanding the different expectations between patients with these conditions is key to choosing the appropriate refractive surgery.

The organization reaffirmed that it stands by myopia defined as a chronic, progression disease.

An effective but underused resource with positive benefits for patients with myopia.

Dye, OD, details exciting new trials for amblyopia that are in the works at NYU Langone Eye Center.

The trial met its primary efficacy and key secondary end points.

The FDA acknowledged the primary efficacy end point was met but determined the data did not confirm the effectiveness of low-dose atropine in children, according to the company.

The researchers noted the importance of comprehensive eye examinations, including cycloplegic refraction for diagnosing and managing common pediatric ocular conditions, especially in children who fail vision screening.

The lens works to slow the progression of myopia in children aged 6 to 12 years at the initiation of treatment.

Study participants were followed annually from 2006 to 2018 with cycloplegic refractions and ocular biometry; the parents were followed with noncycloplegic refractions and ocular biometry.

The Delaying the Onset of Nearsightedness Until Treatment (DONUT) study will be the first of its kind in the US.

Much like the rest of the world, the prevalence of myopia in children in the UK is only growing, having more than doubled in the past 50 years.

A total of 293 optometrists, practice owners, and managers were involved in the survey.

Understanding the scale and scope, by the numbers.

The Japan’s Ministry of Health, Labor, and Welfare approved the lens for manufacturing and sale in the country.

Optometry's Meeting hosted an array of eye care professionals in Minneapolis, Minnesota, from June 25 to 28, 2025.

The DOT lens has now been launched across Asia-Pacific, Europe, and North America, with an estimated 500,000 fitted with DOT lenses in 2025 alone.

One in 3 children worldwide has myopia, and the prevalence is rising so steadily that if it continues as predicted, there will be more than 740 million pediatric cases by 2050.